Plain-English translation of NCT06827860 on ClinicalTrials.gov ↗ · Source last updated ·
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new injectable medication called for older adults whose multiple myeloma has returned or stopped responding to previous treatments. The medication works by helping your body's own immune cells recognize and fight cancer cells. If the medication alone doesn't work well enough after three cycles, doctors will add a second medication () to boost its effectiveness.
Many older patients with returning multiple myeloma cannot safely receive aggressive treatments like stem cell transplants or CAR T-cell therapy, and those whose cancer resists common drug classes have very poor survival rates—sometimes as short as 5 months. This trial aims to find an effective but gentler treatment option specifically for older, frailer patients in early relapse.
You likely qualify if…
You likely don't qualify if…
You will receive the medication as an injection under the skin every other week, with a 28-day treatment cycle. The first week includes three smaller step-up doses to help your body adjust, then you move to the standard dose. Your doctor will check your response to treatment monthly using blood or urine tests. If the medication isn't working well enough after three cycles, will be added to your treatment plan. The study involves regular clinic visits for check-ups, lab work, and monitoring for any side effects.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
United States